Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis

RMD Open

Volumn 3, Issue 1, 2017, Pages

  Huynh, D H ^a   Boyd, T A ^b   Etzel, C J ^c   Cox, V ^c   Kremer, J ^c   Mease, P ^d   Kavanaugh, A ^e,f  

^a Allergy and Rheumatology Clinic   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Corrona LLC ^*  (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PSORIASIS; PSORIATIC ARTHRITIS; REGISTER; RISK ASSESSMENT; SMOKING; TREATMENT DURATION;

EID: 85035318880     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000395     Document Type: Article

References (11)

1. Huynh DH, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 2015; 54:20-8.
2. Boyd T, Kavanaugh A. Novel treatment concepts in psoriatic arthritis. Rheum Dis Clin North Am 2015; 41:739-54.
3. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: R94.
4. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicenter, open-label, randomised controlled trial. Lancet 2015; 386: 2489-98.
5. Kavanaugh A, Lee SJ, Curtis JR, et al. Discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis 2015; 74:1150-5.
6. Yoshida K, Sung YK, Kavanaugh A, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014; 73:595-9.
7. Kremer JM The CORRONA database. Clin Exp Rheumatol 2005; 23:S172-7.
8. Cantini F, Niccoli L, Cassarà E, et al. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics 2012; 6:201-6.
9. Araujo EG, Finzel S, Englbrecht M, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis 2015; 74:655-60.
10. Cantini F, Niccoli L, Nannini C, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008; 47:872-6.
11. Mease P. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis? Clin Exp Rheumatol 2013; 31(suppl 78):S59-62.